POTASSIUM CARBONATE SESQUIHYDRATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2CO3.4K.3H2O
Molecular Weight	330.4568
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of POTASSIUM CARBONATE SESQUIHYDRATE

Structure Search

SMILES

O.O.O.[K+].[K+].[K+].[K+].[O-]C([O-])=O.[O-]C([O-])=O

InChI

InChIKey=WWVGGBSGYNQKCY-UHFFFAOYSA-J

InChI=1S/2CH2O3.4K.3H2O/c2*2-1(3)4;;;;;;;/h2*(H2,2,3,4);;;;;3*1H2/q;;4*+1;;;/p-4

HIDE SMILES / InChI

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH2O3
Molecular Weight	62.0248
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ndrugs.com/?s=kompensan-s%20forte | http://www.catalog.md/drugs/kompensan.html | http://www.nmedication.com/?c=drug&s=kompensan&ingredient=dihydroxyaluminum%20sodium%20carbonate | https://www.ncbi.nlm.nih.gov/pubmed/14367146

Potash (Dihydroxyaluminum Sodium Carbonate), a component of Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.drugbank.ca/drugs/DB09460	Inhibitor 8504
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.drugbank.ca/drugs/DB09460	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastrointestinal disorders 94 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14231249 http://www.ndrugs.com/?s=kompensan-s%20forte https://www.ncbi.nlm.nih.gov/pubmed/13952362 https://www.ncbi.nlm.nih.gov/pubmed/13856278	Primary		Approved 8583	Kompensan Approved Use Gastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia

PubMed

Title	Date	PubMed
Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate.	1991	1669540
Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence.	1990-05-01	2376540
Studies of neutralizing properties of antacid preparations. Part 4: Application of Weibull distribution function to neutralization of dihydroxyaluminum sodium carbonate.	1988-07	3222278
Exchange of sodium by magnesium in aluminum hydroxycarbonate gel.	1984-07	6470941
Studies on antacids. V. The preparation and properties of dihydroxy aluminum sodium carbonate.	1955-04	14367146

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:06:57 GMT 2025` Edited by `admin` on `Mon Mar 31 22:06:57 GMT 2025`
Record UNII	L9300DKS8U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

POTASSIUM CARBONATE SESQUIHYDRATE

Common Name

English

DIPOTASSIUM CARBONATE SESQUIHYDRATE

Preferred Name

English

POTASSIUM CARBONATE (K2CO3) SESQUIHYDRATE

Common Name

English

CARBONIC ACID, DIPOTASSIUM SALT, HYDRATE (2:3)

Systematic Name

English

POTASSIUM CARBONATE 1.5-HYDRATE

Common Name

English

POTASSIUM CARBONATE SESQUIHYDRATE [MI]

Common Name

English

POTASH SESQUIHYDRATE

Common Name

English

Code System Code Type Description

FDA UNII

L9300DKS8U